Non-Hodgkin's lymphoma in childhood

New England Journal of Medicine

Volumn 334, Issue 19, 1996, Pages 1238-1248

  Sandlund, John T ^a,b   Downing, James R ^a   Crist, William M ^a  

^a UNIVERSITY OF TENNESSEE COLLEGE OF MEDICINE   (United States)

^b ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADOLESCENT; CANCER STAGING; CHILD; HUMAN; NONHODGKIN LYMPHOMA; PATHOLOGY; REVIEW; BONE MARROW TRANSPLANTATION; BURKITT LYMPHOMA; CANCER COMBINATION CHEMOTHERAPY; CANCER RECURRENCE; CHILDHOOD CANCER; CHROMOSOME REARRANGEMENT; CHROMOSOME TRANSLOCATION; CLINICAL FEATURE; HISTOLOGY; IMMUNOPHENOTYPING; LARGE CELL LYMPHOMA; LYMPHOBLASTOMA; PRIORITY JOURNAL; PROGNOSIS;

ADOLESCENT; CHILD; HUMANS; LYMPHOMA, NON-HODGKIN; NEOPLASM STAGING;

ANTINEOPLASTIC AGENT; ASPARAGINASE; BLEOMYCIN; CARMUSTINE; CISPLATIN; CYCLOPHOSPHAMIDE; CYTARABINE; DAUNORUBICIN; DOXORUBICIN; ETOPOSIDE; HYDROXYUREA; IFOSFAMIDE; MERCAPTOPURINE; METHOTREXATE; PREDNISONE; TENIPOSIDE; TIOGUANINE; VINCRISTINE;

EID: 0030576183     PISSN: 00284793     EISSN: None     Source Type: Journal    
DOI: 10.1056/NEJM199605093341906     Document Type: Article

References (102)

1. Robison LL. General principles of the epidemiology of childhood cancer. In: Pizzo PA, Poplack DG, eds. Principles and practice of pediatric oncology 2nd ed Philadelphia: J B. Lippincott, 1993:3-10
2. Magrath IT. Malignant non-Hodgkin's lymphomas in children. In. Pizzo PA, Poplack DG, eds Principles and practice of pediatric oncology 2nd ed Philadelphia: J.B. Lippincott, 1993 537-75.
3. Young JL Jr, Ries, LG, Silverberg E, Horm JW, Miller RW Cancer incidence, survival, and mortality for children younger than age 15 years Cancer 1986;58 Suppl:598-602
4. Bleyer WA. The impact of childhood cancer on the United States and the world CA Cancer J Clin 1990,40:355-67.
5. National Cancer Institute sponsored study of classifications of non-Hodgkin's lymphoma summary and description of a working formulation for clinical usage. Cancer 1982;49:2112-35.
6. Hutchison RE, Murphy SB, Fairclough DL, et al. Diffuse small noncleaved cell lymphoma in children, Burkiit's versus non-Burkitt's types: results from the Pediatric Oncology Group and St. Jude Children's Research Hospital Cancer 1989;64:23-8.
7. Murphy SB. Childhood non-Hodgkin's lymphoma N Engl J Med 1978;299:1446-8.
8. Murphy SB, Fairclough DL, Hutchison RE, Berard CW. Non-Hodgkin's lymphomas of childhood an analysis of the histology, staging, and response to treatment of 338 cases at a single institution J Clin Oncol 1989,7 186-93.
9. Parker SL, Tong T, Bolden S, Wingo PA. Cancer statistics, 1996. CA Cancer J Clin 1996;46:5-27
10. Ries LAG, Miller BA, Hankey BF, Kosary CL, Harras A, Edwards BK, eds. SEER cancer statistics review, 1973-1991: tables and graphs. Bethesda, Md.: National Cancer Institute, 1994, (NIH publication no. 94-2789.)
11. Taylor AMR, Metcalfe JA, Thick J, Mak Y-F. Leukemia and lymphoma in ataxia telangiectasia Blood 1996;87:423-38
12. Ellaurie M, Wiznia A, Bernstein L, Rubinstein A. Lymphoma in pediatric HIV infection. Pediatr Res 1989;25:150A. abstract.
13. Pedrosa F, Fonseca T, Leimig T, Verissimo L, Ribeiro RC, Sandlund J. Clinical and biological characteristics of childhood non-Hodgkin lymphoma (NHL) in northeast Brazil. Med Pediatr Oncol 1993;21:532. abstract.
14. Razzouk BI, Srinivas S, Sample CE, Singh V, Sixbey JW. Epstein-Barr virus DNA recombination and loss in sporadic Burkitt's lymphoma. J Infect Dis 1996,173:529-35
15. Gutierrez MI, Bhatia K, Barriga F, et al Molecular epidemiology of Burkitt's lymphoma from South America: differences in breakpoint location and Epstein-Barr virus association from tumors in other world regions. Blood 1992;79 3261-6.
16. Anagnostopoulos I, Herbst H, Niedobitek G, Stein H. Demonstration of monoclonal EBV genomes in Hodgkin's disease and Ki-1-positive anaplastic large cell lymphoma by combined Southern blot and in situ hybridization Blood 1989,74:810-6.
17. Crist WM, Kelly DR, Ragab AH, et al Predictive ability of Lukes-Collins classification for immunologic phenotypes of childhood non-Hodgkin lymphoma an institutional series and literature review Cancer 1981;48.2070-5.
18. Sandlund JT, Hutchison RE, Cost WM. Non-Hodgkin's lymphoma In. Fernbach DJ, Vietti TJ, eds. Clinical pediatric oncology. 4th ed. St Louis. Mosby-Year Book, 1991:337-53.
19. Bernard A, Murphy SB, Melvin S, et al. Non-T, non-B lymphomas are rare in childhood and associated with cutaneous tumor. Blood 1982;59:549-54.
20. Link MP, Roper M, Dorfman RF, Crist WM, Cooper MD, Levy R. Cutaneous lymphoblastic lymphoma with pre-B markers Blood 1983;61 838-41.
21. Cossman J, Chased TM, Fisher RI, Magrath I, Bollum F, Jaffe ES. Diversity of immunological phenotypes of lymphoblastic lymphoma. Cancer Res 1983;43:4486-90.
22. Sandlund JT, Ribeiro R, Lin J-S, et al. Factors contributing to the prognostic significance of bone marrow involvement m childhood non-Hodgkin lymphoma. Med Pediatr Oncol 1994,23:350-3
23. Sandlund JT, Santana V, Abromowitch M, et al. Large cell non-Hodgkin lymphoma of childhood: clinical characteristics and outcome. Leukemia 1994;8:30-4.
24. Hutchison RE, Berard CW, Shuster JJ, Link MP, Pick TE, Murphy SB B-cell lineage confers a favorable, outcome among children and adolescents with large-cell lymphoma: a Pediatric Oncology Group study J Clin Oncol 1995;13:2023-32.
25. Sandlund JT, Pui CH, Santana VM, et al. Clinical features and treatment outcome for children with CD30+ large-cell non-Hodgkin's lymphoma. J Clin Oncol 1994,12.895-8.
26. Stansfeld AG, Diebold J, Noel H, et al. Updated Kiel classification for lymphomas. Lancet 1988,1.292-3. [Erratum, Lancet 1988;1:372.]
27. Kadin ME Ki-1-positive anaplastic large-cell lymphoma. a clinicopathologic entity? J Clin Oncol 1991;9:533-6.
28. Stein HMDY, Mason DY, Gerdes J, et al. The expression of the Hodgkin's disease associated antigen Ki-1 in reactive and neoplastic lymphoid tissue-evidence that Reed-Sternberg cells and histiocytic malignancies are derived from activated lymphoid cells. Blood 1985;66:848-58.
29. Sandlund JT, Pui CH, Roberts WM, et al Clinicopathologic features and treatment outcome of children with large-cell lymphoma and the t(2;5) (p23;q35). Blood 1994,84:2467-71.
30. Kadin ME. Ki-1/CD30+ (anaplastic) large-cell lymphoma: maturation of a clinicopathologic entity with prospects of effective therapy. J Clin Oncol 1994;12:884-7.
31. Haddy TB, Parker RI, Magrath IT. Bone marrow involvement in young patients with non-Hodgkin's lymphoma: the importance of multiple bone marrow samples for accurate staging. Med Pediatr Oncol 1989,17 418-23.
32. Murphy SB Classification, staging and end results of treatment of childhood non-Hodgkin's lymphomas: dissimilarities from lymphomas in adults. Semin Oncol 1980;7.332-9.
33. Sandlund JT, Crist WM, Abromowitch M, et al. Pleural effusion is associated with a poor treatment outcome in stage III small non-cleaved cell lymphoma Leukemia 1991,5:71-4.
34. Patte C, Leverger G, Michon J, et al High survival rate of childhood B-cell lymphoma and leukemia (ALL) as result of the LMB89 protocol of the SFOP. In: Proceedings of the Fifth International Conference on Malignant Lymphoma, Lugano, Switzerland, June 9-12, 1993:52. abstract.
35. Haddy TB, Adde MA, Magrath IT. CNS involvement in small noncleaved-cell lymphomas: is CNS disease per se a poor prognostic sign? J Clin Oncol 1991;9:1973-82
36. Dalla-Favera R, Bregni M, Erikson J, Patterson D, Gallo RC, Croce CM. Human c-myc one gene is located on the region of chromosome 8 that is translocated in Burkitt lymphoma cells. Proc Natl Acad Sci U S A 1982;79:7824-7.
37. Packham G, Cleveland JL Ornithine decarboxylase is a mediator of c-Myc-induced apoptosis. Mol Cell Biol 1994;14.5741-7.
38. Blackwood EM, Eisenman RN. Max: a helix-loop-helix zipper protein that forms a sequence-specific DNA-binding complex with Myc. Science 1991;231:1211-7.
39. Prendergast GC, Lawe D, Ziff EB. Association of Myn, the murine homolog of Max, with c-Myc stimulates methylation-sensitive DNA binding and ras co-transformation. Cell 1991;65:395-407.
40. Ayer DE, Kretzner L, Eisenman RN. Mad: a heterodimeric partner for Max that antagonizes Myc transcriptional activity Cell 1993,72:211-22.
41. Zervos AS. Gyuris J, Brent R Mxil, a protein that specifically interacts with Max to bind Myc-Max recognition sites. Cell 1993;72:223-32. [Erratum, Cell 1994:79 388.]
42. Croce CM, Erikson J, Ar-Rushdi A, Aden D, Nishikura K. Translocated c-myc oncogene of Burkitt lymphoma is transcribed in plasma cells and repressed in lymphoblastoid cells Proc Natl Acad Sci U S A 1984;81:3170-4.
43. Gu W, Bhatia K, Magrath IT, Dang CV, Dalla-Favera R. Binding and suppression of the Myc transcriptional activation domain by p107. Science 1994,264:251-4.
44. Sandlund JT, Neckers LM, Schneller HE, Woodruff LS, Magrath IT. Theophylline induced differentiation provides direct evidence for the deregulation of c-myc in Burkitt's lymphoma and suggests participation of immunoglobulin enhancer sequences. Cancer Res 1993,52:127-32
45. Gu W, Cechova K, Tassi V, Dalla-Favera R Opposite regulation of gene transcription and cell proliferation by c-Myc and Max. Proc Natl Acad Sci U S A 1993;90:2935-9.
46. Packham G, Cleveland JL. c-Myc and apoptosis Biochim Biophys Acta 1995;1242:11-28
47. Adams JM, Harris AW, Pinkert CA, et al The c-myc oncogene driven by immunoglobulin enhancers induces lymphoid malignancy in transgenic mice Nature 1985;318:533-8.
48. Henderson S, Rowe M, Gregory C, et al. Induction of bcl-2 expression by Epstein-Barr virus latent membrane protein 1 protects infected B cells from programmed cell death. Cell 1991;65:1107-15.
49. Roper M, Crist WM, Metzgar R, et al Monoclonal antibody characterization of surface antigens in childhood T-cell lymphoid malignancies. Blood 1983,61:830-7
50. Pui CH, Crist WM. Cytogenetic abnormalities in childhood acute lymphoblastic leukemia correlate with clinical features and treatment outcome. Leuk Lymphoma 1992;7:259-74
51. Xia Y, Brown L, Yang CY, et al. TAL2, a helix-loop-helix gene activated by the (7.9)(p34;q32) translocation in human T-cell leukemia Proc Natl Acad Sci USA 1991,88:11416-20.
52. Mellentin JD, Smith SD, Cleary ML. Lyl-1, a novel gene altered by chromosomal translocation in T cell leukemia, codes for a protein with a helix-loop-helix DNA binding motif. Cell 1989,58:77-83.
53. Kennedy MA, Gonzalez-Sarmiento R, Kees UR, et al HOX11 a homeobox-containing T-cell oncogene on human chromosome 10q24. Proc Natl Acad Sci USA 1991;88:8900-4.
54. Lu M. Gong ZY, Shen WF, Ho AD. The tcl-3 proto-oncogene altered by chromosomal translocation in T-cell leukemia codes for a homeobox protein. EMBO J 1991;10:2905-10.
55. Hatano M, Roberts CW, Minden M, Crist WM, Korsmeyer SJ. Deregulation of a homeobox gene, HOX11, by the t(10,14) in T cell leukemia. Science 1991;253.79-82.
56. Boehm T, Foroni L, Kaneko Y, Perutz MF, Rabbitts TH. The rhombotin family of cysteine-rich LIM-domain oncogenes: distinct members are involved in T-cell translocations to human chromosomes 11p15 and 11p13. Proc Natl Acad Sci U S A 1991,88:4367-71.
57. Bash RO, Crist WM, Shuster JJ, et al Clinical features and outcome of T-cell acute lymphoblastic leukemia in childhood with respect to alterations at the TAL1 locus, a Pediatric Oncology Group study Blood 1993;81:2110-17
58. Hsu H-L, Wadman I, Baer R Formation of in vivo complexes between the TAL1 and E2A polypeptides of leukemic T cells. Proc Natl Acad Sci U S A 1994,91:3181-5.
59. Morris SW, Kirstein MN, Valentine MB, et al. Fusion of a kinase gene, ALK, to a nucleolar protein gene, NPM in non-Hodgkin's lymphoma. Science 1994;263:1281-4. [Erratum, Science 1995,267:316-7.]
60. NPM/ALK: a distinct clinicopathologic entity Blood 1995;86:1954-60.
61. Downing JR, Shurtleff SA, Zielenska M, et al. Molecular detection of (2,5) translocation of non-Hodgkin's lymphoma by reverse transcriptase-polymerase chain reaction. Blood 1995;85:3416-22.
62. Murphy SB, Bowman WP, Abromowitch M, et al. Results of treatment of advanced-stage Burkitt's lymphoma and B cell (Slg+) acute lymphoblastic leukemia with high-dose fractionated cyclophosphamide and coordinated high-dose methotrexate and cytarabine J Clin Oncol 1986;4:1732-9
63. Murphy SB, Hustu HO, Rivera G, Berard CW End results of treating children with localized non-Hodgkin's lymphomas with a combined modality approach of lessened intensity. J Clin Oncol 1983,1:326-30.
64. Link MP, Donaldson SS, Berard CW, Shuster JJ, Murphy SB Results of treatment of childhood localized non-Hodgkin's lymphoma with combination chemotherapy with or without radiotherapy. N Engl J Med 1990,322:1169-74.
65. Link MP, Shuster JJ, Donaldson SS, Berard CW, Murphy SB Treatment of children with localized non-Hodgkin's lymphoma (NHL) with nine weeks of chemotherapy without radiotherapy Med Pediatr Oncol 1993;21:532. abstract.
66. Brecher M, Murphy SB, Bowman P, Sullivan MP, Shuster J, Berard C. A randomized trial of two forms of therapy for stage III diffuse, small non-cleaved cell lymphoma in children Proc Am Soc Clin Oncol 1992;11:430. abstract
67. Bowman WP, Shuster I, Cook B, et al. Improved survival for children with B cell (Slg+) acute lymphoblastic leukemia (B-ALL) and stage IV small non-cleaved cell lymphoma (SNCCL). Proc Am Soc Clin Oncol 1992;11:277. abstract.
68. Patte C, Philip T, Rodary C, et al. High survival rate in advanced-stage B-cell lymphomas and leukemias without CNS involvement with a short intensive polychemotherapy: results from the French Pediatric Oncology Society of a randomized trial of 216 children. J Clin Oncol 1991;9:123-32
69. Patte C, Leverger G, Perel Y, et al. Updated results of the LMB 86 protocol of the French Pediatric Oncology Society (SFOP) for B-cell non Hodgkin's lymphomas (B-NHL) with CNS involvement (CNS+) and B-ALL Med Pediatr Oncol 1990;18:397. abstract
70. Reiter A, Schrappe M, Ludwig WD, et al. Favorable outcome of B-cell acute lymphoblastic leukemia in childhood: a report of three consecutive studies of the BFM Group. Blood 1992;80:2471-8.
71. Anderson JR, Jenkin RDT, Wilson JF, et al. Long-term follow-up of patients treated with COMP or LSA2L2 therapy for childhood non-Hodgkin's lymphoma: a report of CCG-551 from the Childrens Cancer Group. J Clin Oncol 1993;11:1024-32.
72. Chilcote RR, Krailo M, Kjeldsberg C, et al Daunomycin plus COMP vs COMP therapy in childhood non-lymphoblastic lymphomas Proc Am Soc Clin Oncol 1991;10:289. abstract.
73. Cairo MS, Krailo M, Hutchison R, Harris R, Meadows A, Bleyer WA. Results of a phase II trial of "French" (F) (LMB-86) or "orange" (O) (CCG-hybrid) in children with advanced non-lymphoblastic non-Hodgkin's lymphoma: an improvement in survival. Proc Am Soc Clin Oncol 1994;13: 392. abstract.
74. Magrath IT, Janus C, Edwards BK, et al. An effective therapy for both undifferentiated (including Burkitt's) lymphomas and lymphoblastic lymphomas in children and young adults Blood 1984,63:1102-11.
75. Schwenn MR, Blattner SR, Lynch E, Weinstein HJ. HiC-COM: a 2-month intensive chemotherapy regimen for children with stage III and IV Burkitt's lymphoma and B-cell acute lymphoblastic leukemia. J Clin Oncol 1991;9:133-8.
76. Sullivan MP, Boyett J, Pullen J, et al Pediatric Oncology Group experience with modified LSA2-L2 therapy in 107 children with non-Hodgkin's lymphoma (Burkitt's lymphoma excluded) Cancer 1985,55:323-36.
77. Müller-Weihrich S, Henze G, Odenwald E, Riehm H. BFM trials for childhood non-Hodgkin's lymphomas. In. Cavalli F, Bonadonna G, Rozencweig M, eds Malignant lymphomas and Hodgkin's disease: experimental and therapeutic advances Vol. 32 of Developments in oncology. Boston: Martinus Nijhoff, 1985.633-42.
78. Dabi GV, Rivera G, Pui CH, et al. A novel treatment of childhood lymphoblastic non-Hodgkin's lymphoma: early and intermittent use of teniposide plus cytarabine. Blood 1985,66:1110-4.
79. Weinstein HJ, Cassady JR, Levey R. Long-term results of the APO protocol (vincristine, doxorubicin [adriamycin], and prednisone) for treatment of mediastmal lymphoblastic lymphoma. J Clin Oncol 1983;1:537-41.
80. + therapeutic regimen: a Pediatric Oncology Group study. J Clin Oncol 1988;6.26-33.
81. Weinstein HJ, Lack EE, Cassady JR. APO therapy for malignant lymphoma of large cell "histiocytic" type of childhood, analysis of treatment results for 29 patients. Blood 1984;64 422-6.
82. Hvizdala EV, Berard C, Callihan T, et al. Nonlymphoblastic !ymphoma in children - histology and stage-related response to therapy: a Pediatric Oncology Group study. J Clin Oncol 1991,9:1189-95.
83. Santana VM, Abromowitch M, Sandlund JT, et al. MACOP-B treatment in children and adolescents with advanced diffuse large-cell non-Hodgkin's lymphoma Leukemia 1993;7:187-91
84. Murphy SB, Hustu HO. A randomized trial of combined modality therapy of childhood non-Hodgkin's lymphoma. Cancer 1980;45:630-7.
85. Reiter A, Schrappe M, Tiemann M, et al. Successful treatment strategy for Ki-1 anaplastic large-cell lymphoma of childhood: a prospective analysis of 62 patients enrolled in three consecutive Berlin-Frankfurt-Munster group studies. J Clin Oncol 1994;12:899-908.
86. 2 protocol with high dose methotrexate, on 84 children with non-B-cell (lymphoblastic) lymphoma. Med Pediatr Oncol 1992;20.105-13
87. Meadows AT, Sposto R, Jenkin RD, et al. Similar efficacy of 6 and 18 months of therapy with four drugs (COMP) for localized non-Hodgkin's lymphoma of children, a report from the Childrens Cancer Study Group. S Clin Oncol 1989;7:92-9.
88. Patte C, Philip T, Rodary C, et al. Improved survival rate in children with stage III and IV B cell non-Hodgkin's lymphoma and leukemia using multi-agent chemotherapy results of a study of 114 children from the French Pediatric Oncology Society. J Clin Oncol 1986;4:1219-26.
89. 2). N Engl J Med 1983,308:559-65.
90. Magrath I, Adde M, Shad A, et al. Adults and children with small non-cleaved-cell lymphoma have a similar excellent outcome when treated with the same chemotherapy regimen. J Clin Oncol 1996,14:925-34
91. Synold TW, Relling MV, Boyett JM, et al. Blast cell methotrexate-polyglutamate accumulation in vivo differs by lineage, ploidy, and methotrexate dose in acute lymphoblastic leukemia. J Clin Invest 1994;94:1996-2001.
92. Reiter A, Schrappe M, Parwaresch R, et al. Non-Hodgkin's lymphomas of childhood and adolescence: results of a treatment stratified for biologic subtypes and stage - a report of the Berlin-Frankfurt-Munster Group. J Clin Oncol 1995;13:359-72.
93. Lipshultz SE, Colan SD, Gelber RD, Perez-Atayde AR, Sallan SF, Sanders SP. Late cardiac effects of doxorubicin therapy for acute lymphoblastic leukemia in childhood. N Engl J Med 1991;324 808-15.
94. Pui C-H, Ribeiro RC, Hancock ML, et al. Acute myeloid leukemia in children treated with epipodophyllotoxins for acute lymphoblastic leukemia. N Engl J Med 1991;325:1682-7.
95. Wollner N, Burchenal JH, Liebermann PH, Exelby P, D'Angio G, Murphy ML. Non-Hodgkin's lymphoma in children, a comparative study of two modalities of therapy. Cancer 1976;37:123-34.
96. Tubergen DG, Krailo MD, Meadows AT, et al. Comparison of treatment regimens for pediatric lymphoblastic non-Hodgkin's lymphoma. a Childrens Cancer Group study. J Clin Oncol 1995;13.1368-76
97. Magrath I, Adde M, Sandlund J, Jain V. lfosfamide in the treatment of high-grade recurrent non-Hodgkin's lymphomas Hematol Oncol 1991;9: 267-74.
98. Philip T, Hartmann O, Biron P, et al. High-dose therapy and autologous bone marrow transplantation in partial remission after first-line induction therapy for diffuse non-Hodgkin's lymphoma. J Clin Oncol 1988:6 1118-24
99. Philip T, Biron P, Philip I, et al. Massive therapy and autologous bone marrow transplantation in pediatric and young adults Burkitt's lymphoma (30 courses on 28 patients: a 5-year experience). Eur J Cancer Clin Oncol 1986;22:1015-27.
100. Gordon BG, Warkentin PI, Weisenburger DD, et al. Bone marrow transplantation for peripheral T-cell lymphoma in children and adolescents Blood 1992;11:2938-42.
101. Uckun FM, Reaman GH. Immunotoxins for treatment of leukemia and lymphoma. Leuk Lymphoma 1995;18:195-201.
102. Rooney CM, Smith CA, Ng CYC, et al. Use of gene-modified virus-specific T lymphocytes to control Epstein-Barr virus-related lymphoproliferation. Lancet 1995;345:9-13.